The Inhibitory Activity of Typified Propolis against. Enterococcus Species

School of Dental Medicine, University of Pittsburgh, Departments of Oral Biology and Endodontics, 3501 Terrace Street, Pittsburgh, PA 15260, USA.
Zeitschrift fur Naturforschung C (Impact Factor: 0.55). 08/2012; 67(5-6):249-56. DOI: 10.5560/ZNC.2012.67c0249
Source: PubMed


Propolis, a natural bee product widely used for its antimicrobial activity, was tested against isolates of Enterococcus from humans, pig-tailed macaques, isolates of refractory endodontic treatment cases, and isolates from Lactobacillus-containing food supplements. Typification of the propolis was performed by high-performance liquid chromatography (HPLC) by which prenylated compounds, cinnamic acid derivatives, and flavonoids were detected as the main constituents. Minimum inhibitory concentrations (MIC) were determined using the agar dilution method. All human and animal Enterococcus isolates demonstrated MIC values of 1600 microg/mL. Enterococcal species of human and animal origin were inhibited by propolis. Particularly, human isolates of E. faecium and E. faecalis of refractory endodontic treatment cases were susceptible to propolis of Brazilian origin.

Download full-text


Available from: Walter Bretz, Aug 18, 2015
1 Follower
22 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to determine in a randomized, double-blind, placebo-controlled clinical trial the effects of typified propolis and chlorhexidine rinses on salivary levels of mutans streptococci (MS) and lactobacilli (LACT). One hundred patients were screened for salivary levels of MS >100,000 CFUs/mL of saliva. All patients presented with at least one cavitated decayed surface. Sixty patients met entry criteria. Subjects were adults 18-55 years old. After restoration of cavitated lesions patients were randomized to 3 experimental groups: 1) PROP-alcohol-free 2% typified propolis rinse (n = 20); 2) CHX- 0.12% chlorhexidine rinse; 3) PL-placebo mouthrinse. Patients rinsed unsupervised 15 mL of respective rinses twice a day for 1 min for 28 days. Patients were assessed for the salivary levels of MS (Dentocult SM) and LACT (Dentocult LB) at baseline, 7-day, 14-day, and at 28-day visits (experimental effects) and at 45-day visit (residual effects). General linear models were employed to analyze the data. PROP was superior to CHX at 14-day and 28-day visits in suppressing the salivary levels of MS (p < .05). PROP was superior to PL at all visits (p < .01). The residual effects of PROP in suppressing the salivary levels of MS could still be observed at the 45-day visit, where significant differences between PROP and CHX (p < .05), were demonstrated. PROP was significantly superior than CHX in suppressing the levels of salivary LACT at the 28-day visit (p < .05). Typified propolis rinse was effective in suppressing cariogenic infections in caries-active patients when compared to existing and placebo therapies.
    04/2013; 16(2):31-36. DOI:10.14295/bds.2013.v16i2.879
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The need to discover and develop alternative therapies to treat multidrug-resistant bacterial infections is timely. The aim of this study was to examine the antimicrobial potential of propolis, as a purified and concentrated special extract GH 2002, against clinical isolates of Streptococcus pyogenes, methicillin-resistent Stapylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE) and Candida. Minimal inhibitory concentrations (MICs) and minimal microbicidial concentrations (MMCs) of propolis against microbial pathogens were evaluated using the broth microdilution method. Propolis extract GH 2002 revealed low MICs in the range of 0.03 to 2 mg/ml against S. pyogenes, S. aureus, E. faecium and Candida. A high bactericidal activity of propolis extract in the range of 0.06 to 1.0 mg/ml was determined for S. pyogenes and S. aureus, however propolis was not bactericidal against E. faecium. Propolis concentrations between 0.6 and 2.4 mg/ml displayed fungicidal activity against different Candida species. Whereas all tested MRSA strains were highly susceptible against propolis, only minor activity was found against VRE strains. Time-kill curves demonstrated a high antimicrobial activity at low MICs already after few hours of incubation against reference strains, clinical antibiotic-susceptible strains, clinical antifungal susceptible strains as well as all tested clinical MRSA strains, but not against VRE strains. In conclusion, clinical drug-sensitive as well as some clinical multidrug-resistant microbial isolates, i.e. MRSA, were susceptible to propolis with different degrees of susceptibility. These results suggest that the special propolis extract GH2002 might be used in the development of alternative products for therapy of microbial infections.
    Pharmazie 08/2013; 68(8):695-701. DOI:10.1691/ph.2013.2907 · 1.05 Impact Factor
  • Source
Show more